Cullinan Management (CGEM) Price & Analysis

Compare

292 Followers

CGEM Stock Chart & Stats

$11.74

-$0.28(-2.38%)

At close: Jan 08 4:00 PM EST

$11.74

-$0.28(-2.38%)

Day’s Range― - ―

52-Week Range$5.68 - $13.78

Previous CloseN/A

Volume73.34K

Average Volume (3M)1.16M

Market Cap

$693.56M

Enterprise Value$18.91M

Total Cash (Recent Filing)$332.60M

Total Debt (Recent Filing)$1.19M

Price to Earnings (P/E)―

Beta0.97

Next Earnings

Mar 05, 2026

EPS Estimate

-0.82

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.77

Shares Outstanding59,076,260

10 Day Avg. Volume1,575,708

30 Day Avg. Volume1,163,314

Financial Highlights & Ratios

PEG Ratio0.25

Price to Book (P/B)1.11

Price to Sales (P/S)0.00

P/FCF Ratio-4.51

Enterprise Value/Market Cap0.03

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-248.77

Enterprise Value/Ebitda-0.08

Forecast

1Y Price Target

$30.20

Price Target Upside157.24% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-3.59

Revenue Forecast (FY)$6.12M

Bulls Say, Bears Say

Bulls Say

Financial PositionCullinan ended 3Q25 with $475.5M in cash and cash equivalents, which should provide an operational runway into 2029 through multiple key data catalysts.

Regulatory MilestonesCullinan is eligible to receive up to $130 million in payments for EGFR ex20ins NSCLC U.S. regulatory milestones.

Therapeutic DevelopmentCullinan's CLN-049 demonstrates competitive efficacy in AML, with potential broader applicability across a range of patients.

Bears Say

Adverse EventsThe most common TEAEs included CRS, infusion-related reaction, febrile neutropenia, pneumonia, stomatitis, and white blood cell count decrease.

Clinical Trial RisksRisks include slower-than-expected enrollment in trials, negative efficacy data, inability to receive FDA approval, and potential superior data from competitor agents.

Financial RisksPossible medium- to long-term dilution risk is mentioned as a concern for Cullinan.

Cullinan Management News

Cullinan Therapeutics price target raised to $38 from $32 at BTIG

BTIG analyst Julian Harrison raised the firm’s price target on Cullinan Therapeutics (CGEM) to $38 from $32 and...

5d ago

CGEM

Taiho, Cullinan Therapeutics initiate rolling submission of NDA for zipalertinib

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) announced the companies have initiated the rolling submission of a...

9d ago

CGEM

Cullinan Therapeutics price target raised to $26 from $24 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Cullinan Therapeutics (CGEM) to $26 from $24 and keeps a...

9d ago

CGEM

Cullinan Therapeutics reports Q3 EPS (77c), consensus (89c)

“Cullinan is strategically focusing resources and development efforts on select, high-conviction clinical stage programs. We are well-positioned to...

23d ago

CGEM

Cullinan Therapeutics to showcase new data from Phase 1 study of CLN-049

Cullinan Therapeutics (CGEM) announced new clinical data from its Phase 1 study of CLN-049, a novel, investigational FLT3xCD3...

26d ago

CGEM

Buy Rating for Cullinan Therapeutics Driven by Promising AML Treatment Developments and Strong Market Potential

JonesTrading analyst Soumit Roy has reiterated their bullish stance on CGEM stock, giving a Buy rating on November...

3d ago

CGEM

Cullinan Management Ends Development of CLN-617

Cullinan Management ( ($CGEM) ) has provided an announcement. On November 18, 2025, Cullinan Amber Corp., a subsidiary...

8d ago

CGEM

Promising Developments and Strategic Partnerships Boost Cullinan Management’s Growth Prospects

Cullinan Management, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Julian Harrison from...

8d ago

CGEM

Optimistic Buy Rating for Cullinan Management Driven by Promising Drug Pipeline and Upcoming Catalysts

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Cullinan Management, boosting the price target to...

9d ago

CGEM

Cullinan Management’s Promising Pipeline and Strategic Collaborations Drive Buy Rating

Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on Cullinan Management. The associated price target remains...

18d ago

CGEM

Cullinan Therapeutics Reports Increased Q3 Losses

Cullinan Management, Inc. ( ($CGEM) ) has released its Q3 earnings. Here is a breakdown of the information...

23d ago

CGEM

Cullinan Management: Strong Financials and Promising Pipeline Justify Buy Rating

TD Cowen analyst Marc Frahm has maintained their bullish stance on CGEM stock, giving a Buy rating today....

23d ago

CGEM

Cullinan Management’s Promising Pipeline and Strategic Focus Earns Buy Rating

William Blair analyst Matt Phipps has maintained their bullish stance on CGEM stock, giving a Buy rating on...

23d ago

CGEM

Cullinan Management Reports Strong Q3 2025 Financial Results

Cullinan Management ( ($CGEM) ) has shared an update. Cullinan Therapeutics announced its financial results for the third...

23d ago

CGEM

CGEM FAQ

What was Cullinan Management’s price range in the past 12 months?

Cullinan Management lowest stock price was $5.68 and its highest was $13.78 in the past 12 months.

What is Cullinan Management’s market cap?

Cullinan Management’s market cap is $693.56M.

When is Cullinan Management’s upcoming earnings report date?

Cullinan Management’s upcoming earnings report date is Mar 05, 2026 which is in 96 days.

How were Cullinan Management’s earnings last quarter?

Cullinan Management released its earnings results on Nov 06, 2025. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.947 by $0.177.

Is Cullinan Management overvalued?

According to Wall Street analysts Cullinan Management’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cullinan Management pay dividends?

Cullinan Management does not currently pay dividends.

What is Cullinan Management’s EPS estimate?

Cullinan Management’s EPS estimate is -0.82.

How many shares outstanding does Cullinan Management have?

Cullinan Management has 59,076,260 shares outstanding.

What happened to Cullinan Management’s price movement after its last earnings report?

Cullinan Management reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.947. Following the earnings report the stock price went up 0.547%.

Which hedge fund is a major shareholder of Cullinan Management?

Currently, no hedge funds are holding shares in CGEM

Cullinan Management Stock Smart Score

Neutral

Fundamentals

Return on Equity

-40.18%

Trailing 12-Months

Asset Growth

-25.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cullinan Management

Cullinan Oncology, Inc. (CGEM) is a clinical-stage biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies. The company operates in the biotechnology sector and is dedicated to advancing its portfolio of novel cancer treatments to address unmet medical needs. Cullinan leverages a rigorous scientific approach to discover and develop innovative therapies that target specific cancer pathways.

Cullinan Management (CGEM) Earnings & Revenues

Historic Earnings Reports

CGEM Stock 12 Month Forecast

Average Price Target

$30.20

▲(157.24% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","22":"$22","39":"$39","13.5":"$13.5","30.5":"$30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$23.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,13.5,22,30.5,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.66,10.916923076923077,13.173846153846153,15.430769230769231,17.68769230769231,19.944615384615382,22.201538461538462,24.45846153846154,26.715384615384615,28.97230769230769,31.229230769230767,33.48615384615384,35.74307692307693,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.66,10.316923076923077,11.973846153846154,13.630769230769232,15.287692307692307,16.944615384615386,18.60153846153846,20.25846153846154,21.915384615384617,23.572307692307692,25.22923076923077,26.886153846153846,28.543076923076924,{"y":30.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.66,9.763076923076923,10.866153846153846,11.96923076923077,13.072307692307692,14.175384615384615,15.278461538461539,16.38153846153846,17.484615384615385,18.587692307692308,19.69076923076923,20.793846153846154,21.896923076923077,{"y":23,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.76,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.78,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.18,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.56,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >